Metabolomics: Global Strategic Business Report

Global Metabolomics Market to Reach $8.1 Billion by 2030

The global market for Metabolomics estimated at US$1.9 Billion in the year 2022, is projected to reach a revised size of US$8.1 Billion by 2030, growing at a CAGR of 19.9% over the analysis period 2022-2030. Biomarker Discovery, one of the segments analyzed in the report, is projected to record 22.1% CAGR and reach US$3.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Drug Discovery segment is readjusted to a revised 19.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $554.7 Million, While China is Forecast to Grow at 19% CAGR

The Metabolomics market in the U.S. is estimated at US$554.7 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 19% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.7% and 16.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.

Select Competitors (Total 31 Featured) -

• AB Sciex LLC
• African Biosciences Ltd
• Agilent Technologies, Inc.
• Agios Pharmaceuticals, Inc.
• Berg LLC
• BioCat GmbH
• Biocenter Finland
• Biocrates Life Sciences AG
• Biogenetics
• Bio-Rad Laboratories, Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year